Abstract. Human African trypanosomiasis is an infectious disease which has resulted in the deaths of thousands of people in Sub-Saharan Africa. Two subspecies of the protozoan parasite Trypanosoma brucei are the causative agents of the infection, whereby T. b. gambiense leads to chronic development of the disease and T. b. rhodesiense establishes an acute form, which is fatal within months or even weeks. Current chemotherapy treatment is complex, since special drugs have to be used for the different development stages of the disease, as well as for the parasite concerned. Melarsoprol is the only approved drug for effectively treating both subspecies of human African trypanosomiasis in its advanced stage, however, the drug's potency is constrained due to an unacceptable side effect: encephalopathy, which develops in one out of every 20 patients who are treated with the drug. In addition to the deleterious treatment with melarsoprol, the number of drugresistant strains of T. brucei supp. increases. Mechanisms of drug resistance have been elucidated and involve decreased drug import through the loss of the purine transporter P2 as well as enhanced drug export, mediated by a multidrug resistance-associated protein called TbMRPA. Thereby, the medical treatment with the available chemotherapeutics becomes exceedingly difficult. A promising strategy for research into new drugs and moreover, to overcome drug resistance, are compounds derived from natural sources. This study provides an overview of the recently discovered small molecules with trypanocidal activity against T. b. gambiense and T. b. rhodesiense. In addition, former promising compounds are touched upon.
Introduction
Human African typanosomiasis is a vector-born parasitic disease demonstrating a major public health problem for people in the Sub-Saharan region. The transmission of the disease is heightened due to lack of hygiene and close relationship between humans and domestic mammals. Furthermore, endemics develop in rural areas where medical facilities needed for an effective treatment are missing (1) . Resistance is a broad problem in the fight against this infectious disease. Except for the limited drugs used currently in chemotherapy, no other drugs are available, if strains were to develop resistance.
The search for new drugs is difficult and drug development generally takes years. The easiest strategy is derivatisation of approved drugs, to achieve improved pharmacokinetics and changes in the anti-protozoal activity. Nevertheless, the mode of action stays the same, and resistant strains are not highly sensitive to derivatives and frequently develop resistance to structurally related substances as well. Another problem is that standard chemotherapeutics often exhibit unconfirmed risks to patients. Due to serious side effects maximal dosages, needed for the complete eradication of the parasite, and thereby, avoiding development of resistance, are deleterious (2) . This shows a strong need for research into novel drugs for the treatment of human African trypanosomiasis, to develop safe, effective drugs, and to overcome drug resistance.
Active substances can chemically be synthesized or, alternatively, can also be identified in natural sources with high diversity of chemical structures. The most common of which is the use of plant-derived compounds in medical application, but even fungi, bacteria, and animals can be a source for chemical substances with potency for treatment of diseases (3).
Of special interest are compounds, which are not generally cytotoxic, but show trypanocidal specificity. By serving as novel lead compounds, their structures can be optimized by semi-synthetic or fully synthetic derivatization (4) . In the fields of pharmacology and pharmacy, natural products have always played an important role in combating diseases. Famous examples are the glycosides digitoxin, isolated from Digitalis purpurea and digoxin, derived from D. lanata, which are applied against cardiac diseases. Other examples are demonstrated by the alkaloids vincristine and vinblastine, purified from the plant Vinca rosea (Catharanthus roseus) and paclitaxel, isolated from Taxus brevifolia, which are naturally derived anticancer drugs (1) . These successes demonstrate that natural products are a potent source for the development of drugs against a variety of diseases and in particular, to give an impact on the treatment of human African trypanosomiasis by drugs that follow different mechanisms of action, thereby, increasing their efficiency and avoiding development of drug resistance. Other strategies to limit the number of infections are either to address the parasite in its vector or to combat the vector itself (5).
Disease and clinical manifestation
Human African trypanosomiasis, also known as sleeping sickness, has been resurgent in Sub-Saharan Africa since the late 1990s (5), and today 50 million people are at risk of becoming infected with the disease (6) . Although, progress in disease control has been made, the World Health Organization (WHO) estimated in 2005 that the number of infections lies between 50,000-70,000 (7) . Human African trypanosomiasis is caused by two morphologically indistinguishable subspecies of the hemoflagellated protozoan parasite Trypanosoma brucei, which are transmitted to the human host each by a specific species of the genus Glossina, known as tsetse fly. Both vectors inhabit distinct areas of Africa, leading to an epidemiological division of the causative agents of the disease. In West Africa, T. b. gambiense is transmitted primary to humans by G. palpalis, whereas in East Africa G. morsitans play a role as a vector for incidental transmission of T. b. rhodesiense to humans, while generally infecting domestic mammals (6) .
According to the appearance of trypanosomes in the vector and the mammalian host, the life cycle of Trypanosoma brucei is digenetic. Procyclic forms of trypanosomes exist in the tsetse flies' mid gut, where they develop into epimastigotes and leave the mid gut to transform into metacyclic infective trypomastigotes in the salivary glands of the fly. The mammalian host gets involved in the life cycle during a blood meal of the fly. Thereby, metacyclic trypomastigotes are inoculated into the skin and infest the blood system. In the host, they transform into bloodstream trypomastigotes, which divide by binary fission in the blood, lymph and extra cellular spaces. Characteristic for the African trypanosomiasis is that no intracellular form exists. The parasites re-enter the tsetse fly, when an infected mammal is bitten again and redevelop into procyclic trypomastigotes (8) . For the infected human the disease develops from a first hemolymphatic stage with mild symptoms, including fever, headaches, joint pains and itching, into a second stage, where the parasites cross the blood brain barrier and establish a cerebral infection.
At the second stage, being more adverse, the patient suffers from torture of the central nerve system. Severe headaches, loss of nocturnal sleep, mental disorientation, tremors of tongue, hands and feet, and any neurological psychiatric manifestation are the outcome. Finally, patients fall into coma and die of opportunistic infections (6) . The timed development of symptoms and the life expectancy strongly depend on the T. brucei subspecies with which the human is infected. A chronic disease is caused by T. b. gambiense, which is mostly asymptomatic for months or even years. When symptoms appear, the parasites have already infected the central nervous system. In contrast, an acute infection is caused by T. b. rhodesiense within weeks or months. In this case, the disease rapidly affects the central nervous system and is fatal for untreated patients (7) .
In order to approach the defense against the protozoan parasite, differences in biochemical mechanisms between parasite and host are promising drug targets without expected cytotoxicity towards the human host (9) . A particularity of Trypanosoma is constituted by its single mitochondrion, which possesses a high number of circular DNA, organized to an interlocked and super-coiled network, called kinetoplast DNA (kDNA). As a result, Trypanosoma is classified as a Kineplastida. The kDNA renders the mitochondrial replication as a high energetic process, and while divergent to the human host, it serves as a potential drug target (10) .
To manage the carbohydrate metabolism, Trypanosoma has developed alternative pathways, including the glycosome. This is a special organelle in which part of the glycolysis is compartmentalized (11) . Another specific characteristic is demonstrated by trypanothione and trypanothione reductase, both essential for the parasite's defense against oxidative stress (12) . Trypanothione is built by a covalent complex of two glutathiones linked by the polyamine spermidine (13) . The polyamine synthesis, maintained by the enzymes S-adenosylmethionine decarboxylase (SAMDC) and ornithine decarboxylase (ODC), is therefore also a potential drug target. Alteration leads to an impaired generation of trypanothione, whereby the parasite becomes susceptible to oxidative stress. (14, 15) . In addition, trypanosomes lack de novo purine synthesis as well as synthesis of cholesterol and fatty acids, making the parasite obligated to supply of these molecules from the host (16, 17) .
Given that the parasites stay extracellular, the host's immune system recognizes an infection with T. brucei supp., initiating a humoral immune response (3) . Nevertheless, eradication is not achieved, since the parasite evades the immune system mainly by switching of variant surface glycoproteins (VSG) each generation (15) . Thereby, the generation of antibodies no longer recognizes the parasites' surface antigens, enabling the parasite always to be one step in front of the hosts' immune defense mechanisms, therefore, all efforts to develop a vaccine against trypanosomiasis have not been effective (3).
Standard chemotherapy
The treatment of human African trypanosomiasis is challenging due to the fact that drugs have to be efficient against the two subspecies of T. brucei and the two developmental stages of the disease. To fulfill these demands, chemotherapy has to be co-ordinated to each case (18) . Pentamidin, a water soluble aromatic diamidine with amidine groups at either end, is applied in the early stage of the disease (15) , but its efficiency is restricted to T. b. gambiense (19) . Pentamidin enters the parasite via the purine transporter P2, a protein primarily responsible for the transport of adenosine and adenine (20) . Due to the transported molecules and drugs, the recognition motif is likely to be constituted by amidine nitrogens (21) .
Pentamidine possesses trypanocidal activity by binding to a minor groove of kDNA in the mitochondrion, thereby, inducing changes in DNA topology and inhibiting topoisomerases (22, 23) . As a result, the replication of the mitochondrion is impaired and DNA cleavage occurs. Moreover, pentamidin has been identified as inhibitor of the S-adenosylmethionine decarboxylase (24) , resulting in inhibition of the polyamine synthesis and in turn lack of trypanothione. Suramin, a sulfonated naphthylamine, is the second early stage drug applied in infections with T. b. rhodesiense (25). Exhibiting binding affinities to many plasma proteins, including low density lipoprotein (LDL) (25), suramin is taken up via receptor-mediated LDL endocytosis. It has been shown to inhibit various glycolytic enzymes, as well as receptor-mediated LDL uptake, among other activities (26, 27) .
Its trypanocidal action is probably constituted by inhibition of LDL uptake, prohibiting the parasite's supply of cholesterol and phospholipids. For the treatment of late stage human African trypanosomiasis melarsoprol, a melaminophenyl arsenical, is the drug of first choice by providing efficiency against T. b. gambiense and T. b. rhodesiense (28) . After its uptake into the trypanosome via P2 (15) melarsoprol is degraded to melarsen oxide, a metabolite which has been shown to be highly toxic in vivo and causing in rapid lysis of the parasites (29) . Furthermore, melarsoprol interacts with trypanothione forming a stable complex, called MelT, which in turn is an inhibitor of the trypanothione reductase (30, 31) .
Inhibition of trypanothione reductase and decrease of trypanothione level by formation of adducts act two-fold to impair the parasite's defence against oxidative stress. There is no doubt that the application of melarsoprol is crucial to combat late stage infections, but the application of this drug is hampered by its adverse side effects (28) . Most prominently, encephalopathy causes mortality in five percent of treated patients (3). A newer late stage drug, α-difluoromethylornithine (DMFO, eflornithine) (32), is safer, but only possesses efficiency against T. b. gambiense (33) . It enters the parasite via passive diffusion (34) and acts as an irreversible inhibitor of the ornithine decarboxylase (ODC) (35, 36) . Thereby, the polyamine synthesis is inhibited, resulting in a decreased level of redox regulator trypanothione (19) .
It has been elucidated that the lack of efficiency against T. b. rhodesiense is caused by a faster turnover rate of its ODC-enzymes (34) . As a result, inhibited ODCs are replaced faster in T. b. rhodesiense. Additionally, substrates in the pathway of polyamine synthesis are accumulated, and in particular, the S-adenosylmethionine level increases, which might disrupt normal methylation patterns of proteins and other cell components (37).
Development of resistance
The development of drug resistance is caused by different mechanisms. Altered metabolic pathways prevent the drug from reaching its target. Alternative pathways facilitate the parasites' independence on inhibited targets or detoxification of the drug. In addition, intracellular accumulation of the drug can be inhibited by decreased drug import or increased drug export (38) .
Due to the extensive use of drugs and their structural similarities, multiple drug resistance has developed (3). Resistance in T. b. rhodesiense and T. b. gambiense is frequently mediated by reduced net drug uptake. Reduced drug import is mediated primarily via loss of P2, also named TbAT1 (for Trypanosoma brucei adenosine transporter 1) (15) . Additionally, silent and coding point mutations in the TbAT1 gene lead to changes in substrate specificity (39) .
Surprisingly, loss of P2 induces only a small increase of resistance towards melarsoprol and pentamidine (2-3-fold) (18) . This might be due to a P2-independent uptake of melarsoprol and pentamidine by additional transporters. One transporter identified is HAPT1 (high-affinity pentamidine transporter), which mediates supplemental import of melarsoprol. Therefore, high-level melarsoprol resistance might be caused by loss of both transporters, P2 and HAPT1 (18) .
Another drug resistance mechanism for melarsoprol represents the overexpression of the efflux pump TbMRPA (10-fold) (15, 40) . TbMRPA is one of three ATP-binding cassette transporters present in Trypanosoma brucei (41) . It belongs to the sub-family of multidrug resistance-associated proteins (MRPs), characterized by the need of ATP and thiols to transport molecules against a concentration gradient (42). TbMRPA functions as a detoxification efflux pump localized in the plasma membrane of the parasite and mediates the efflux of MelT (15, 40) .
Other resistance mechanisms, unrelated to drug transport, have also been observed emphasizing the multifactorial nature of drug resistance (15) . As a result, emergence of drug resistance hinders efforts to control the disease (18) . Increase in treatment failures with melarsoprol, and more importantly, its unacceptable side effect encephalopathy, shows the urgent need for new trypanocidal agents (3). Due to the fact that DMFO is not effective against T. b. rhodesiense, there is no safe and efficient drug that crosses the blood-brain barrier to treat the late stage human African trypanosomiasis. In addition, early stage chemotherapeutics have to be administered parenterally, which makes the treatment impossible in areas, where no medical facilities exist (43).
Screening of natural products
The potential of natural products in the treatment of diseases can be seen in traditional medicines. Since treatments with medicinal plants were developed over thousands of years and are still practised today, it might be promising to search for plants traditionally used to treat sleeping sickness and to investigate their bioactive chemical constituents (1) . To permit meaningful investigations on a molecular level, it is important to focus strictly on isolated compounds from plant raw extracts (44) .
A previous review of Hoet and co-workers presents a wide variety of compounds isolated from natural sources with trypanocidal activity reported in publications from mid-1980 to June 2003 (45) . Therefore, the present overview focuses on a summary of the latest results in the field and concomitantly a comprehensive overview is provided by displaying the most promising compounds again. Furthermore, the present overview is restricted to compounds from natural products exhibiting activity against T. b. gambiense and T. b. rhodesiense. Beside the determination of the trypanocidal effect itself, most studies in the literature also describe the cytotoxicity of natural products towards a mammalian cell line.
Taking both measures into account, the selectivity index (SI) can be calculated by dividing the IC 50 value of a compound for a mammalian cell line through the IC 50 for its trypanocidal action. The SI indicates, whether a compound is generally cytotoxic (low SI) or specifically affects the parasite (high SI). Compounds with high SI values are suitable for in vivo studies. The reader should keep in mind that the data in the literature were generated in different experimental settings. Therefore, the values are not fully comparable.
Where possible, we indicate the activity of a reference drug, melarsoprol, to allow the reader at least some comparability between different investigations. To constrain the huge number of compounds reported in the literature, only those which possess trypanocidal activity in concentrations <80 μM were considered in the present review. The trypanocidal substances are organised according to their chemical structure (Figs. 1-4) .
Alkaloids ( Fig. 1 ): Ancistrolikokine D [1], a naphthylisoquinoline alkaloid, was isolated from Ancistrocladus likoko (Ancistrocladaceae), a tropical liana indigenous to the rainforests of Central Africa. The IC 50 value was 2.71 μg/ml (6.9 μM) on bloodstream forms of T. b. rhodesiense, and a SI value of 13.5 was obtained when compared to mammalian L6 cells (rat skeletal myoblasts). For the reference drug, melarsoprol, an IC 50 value of 0.0026 μg/ml (0.007 μM) was obtained (46) . Several naphthylisoquinoline alkaloids, ancistrocladidine [2] , ancistrotectorine [3] , ancistrotanzanine C [4] , O-methylancistrocladinine [5] and O,N-dimethylancistrocladine [6] , were isolated from Ancistrocladus tarzanienses. The IC 50 values were 2.0, 4.3, 1.3, 5.2 and 5.4 μg/ml (4.7, 9.9, 3.2, 12.4 and 12.4 μM), respectively, on bloodstream forms of T. b. rhodesiense, and SI values were 14.2, 4.6, 31.3, >17, and 7.9 when compared to L6 cells. For the reference drug, melarsoprol, an IC 50 value of 0.0031 μg/ml (0.008 μM) was obtained (47) .
In addition to these studies, highly structurally related naphthylisoquinoline alkaloids were isolated from another species of Ancistrocladus. Ent-dioncophylleine A [7] , 5'-Odemethyl-ent-dioncophylleine A [8] and dioncophylleine D [9] , derived from A. benomensis, exhibited IC 50 values of 5.6, 1.4 and 4.7 μg/ml (15.0, 3.9 and 12.6 μM) on bloodstream forms of T. b. rhodesiense. In the applied concentrations 5'-O-demethyl-ent-dioncophylleine possessed cytotoxicity to L6 cells with a SI value of 14.6. For the reference drug, melarsoprol, an IC 50 value of 0.00095 μg/ml (0.002 μM) was obtained (48) .
Pancracine [10] , an isoquinone alkaloid, was isolated from the bulb of Narcissus augustifolius transcarpathius (Amaryllidaceae). The IC 50 value was 0.7 μg/ml (2.4 μM) on bloodstream forms of T. b. rhodesiense. At concentrations ≤300 μM, no cytotoxicity was observed when compared to L6 cells. For the reference drug, melarsoprol, an IC 50 value of 0.0014 μg/ml (0.004 μM) was obtained (49) .
Lepadin E [11] and lepadin F [12] , both decahydroquinolines derivates, were isolated from a novel species of the tunicate Didemnum (Didemnidae). The IC 50 values for the two diastereoisomers were 0.38 and 0.23 μg/ml (0.9 and 0.5 μM), respectively, on bloodstream forms of T. b. rhodesiense. The compounds showed moderate selectivity towards the parasite with SI values of 43 and 80 when compared to L6 cells. For the reference drug, melarsoprol, an IC 50 value of 0.0026 μg/ml (0.007 μM) was observed (50) .
Ascididemin [13] and 2-bromoascididemin [14] , two pyridoacridone alkaloids derived from a marine organism, possessed trypanocidal activity in vitro. Ascididemin is known to exhibit anti-tumor activity by DNA intercalation. The IC 50 values were 4 and 1.76 μg/ml (14 and 5 μM), respectively, on bloodstream forms of T. b. rhodesiense, and SI values of 0.1 and 0.4 were observed when compared to L6 cells. For the reference drug melarsoprol an IC 50 value of 0.0012 μg/ml (0.003 μM) was obtained. The presence of a benzonaphthyridone substructure seems to be important for the trypanocidal activity. It has been suggested that the compounds intercalate into the DNA and induce oxidative damage. Nevertheless, the potential of the substances is limited due to their high cytotoxicity. By synthetic derivatization related compounds were obtained, which possessed significantly higher specificity towards the parasite. For two compounds [15, 16] the IC 50 values were 0.002 and 0.005 μg/ml (0.007 and 0.018 μM), respectively, on bloodstream forms of T. b. rhodesiense, and SI values 950 and 316 were observed when compared to L6 cells (51) . Phenolics ( Fig. 2 ): 3-geranyloxy-6-methyl-1,8-dihydroxyanthraquinone [17] , emodin [18] and bianthrone A1 [19] , all anthraquinones, as well as vismione D [20] , an tetrahydroanthracene derivative, were isolated from the stem bark of Vismia orientalis (Guttiferae or Clusiaceae), a plant used in traditional medicine in Tanzania. Vismione D exhibited moderate activity with an IC 50 value of 9 μg/ml (22 μM (52) .
Lanaroflavone [21] , a biflavonoid, was isolated from Campnosperma panamense (Anacardiaceae) collected in Southern Columbia. Other biflavonoids, bilobetin [22] , ginkgetin [23] , isoginkgetin [24] and sciadopitysin [25] , were derived from Ginkgo biloba (Ginkgoaceae). The IC 50 values were 27, 8.9, 7.0, 3.5 and 7.0 μM, respectively, on bloodstream forms of T. b. rhodesiense, and SI values were 2.6, 2.9, 1.3, 3.1 and 9.7 when compared to L6 cells. Therefore, isoginkgetin possessed the highest trypanocidal activity, but without adequate specificity towards the parasite. For the reference drug, melarsoprol, an IC 50 value of 0.005 μM was obtained (53) .
Ambigol A [26] and ambigol C [27] , two chlorinated aromatic compounds, were isolated from the terrestrial cyanobacterium Fischerella ambigua. The minimal inhibitory concentrations (MIC) were 33 and 11 μg/ml (68 μM and 22.7 μM), respectively, on bloodstream forms of T. b. rhodesiense. Whereas ambigol A showed no selectivity toward the parasite with an SI value of 1 when compared to L6 cells, the SI value for ambigol C was 9.1. No reference drug was used (54).
Tasdemir and coworkers screened a large number of flavonoids and analogues for their trypanocidal activity in vitro. The most potent compound was the natural product 7,8-dihydroxyflavone [28] , followed by 3-hydroxyflavone [29] , rhamnetin [30] Justicidin B [32] , an arylnaphthalide lignan, was isolated as the main active principle of Phyllanthus piscatorum (Euphorbiaceae). The raw extract of the plant is used for topical treatment of Candida albicans infections of the vagina. The IC 50 value was 0.2 μg/ml (0.55 μM) on bloodstream forms of T. b. rhodesiense with an SI value of 16.5 when compared to L6 cells. However, a high cytotoxicity demonstrated by an SI value of 1 was observed when compared to HeLa cells. For the reference drug, melarsoprol, an IC 50 value of 0,003 μg/ ml (0.0008 μM) was obtained (55) .
2-(1-hydroxyethyl)-naphato [2,3-b] furan-4,9-quinone [33] , a furanonaphtoquinone and iso-pinnatal [34] , a naphthoquinone, were isolated from Kigelia pinnata (Bignoniaceae). In Africa K. pinnata is a medial plant for the treatment of dysentery and venereal disorders and also used topically to deal with wounds and abscesses. The IC 50 values of both compounds were 0.045 and 0.73 μM, respectively, on bloodstream forms of T. b. rhodesiense and SI values of 86.7 and 20.3 were observed when compared to KB cells (human oral epidermal cell line). For the reference drug pentamidine, an IC 50 value of 0.016 μg/ml (0.047 μM) was obtained (56) .
Glycosides ( Fig. 3 ): Resin glycosides, crypthophilic acid A [35] and crypthophilic acid C [36] as well as buddlejasaponin III [37] , were isolated from Scrophularia cryptophila (Scrophulariaceae). The compounds exhibited growthinhibitory effect on bloodstream forms of T. b. rhodesiense with IC 50 values of 46.9, 14.1, and 9.7 μg/ml (51.8, 13.5 and 10.8 μM), repsectively. For the reference drug, melarsoprol, an IC 50 value of 0.0098 μg/ml (0.025 μM) was obtained. None of the isolates was toxic to L6 cells (57) .
Angoroside C [38] , a phenylethanoid glycoside, was isolated from the roots of Scrophularia lepidota (Scrophulariaceae), a plant endemic of the Turkish flora. nucleophils. Moreover, the compounds display two alkylation centres, a cyclopentenone and the α-methylene-γ-lactone moieties, mediating interactions with sulphhydryl groups of various enzymes. This bifunctionality is hypothesised to increase the specificity towards the parasite compared to monofunctional sesquiterpene lactones, which possessed higher cytotoxicity than trypanocidal activity. In addition, stereochemistry seems to play an important role, since mexicanin I, a diastereoisomer of helenalin, was six times less active. The mode of action is anticipated to involve the trypanothione metabolism to increase oxidative stress in the parasite (60) .
Other metabolites (Fig. 4) : Harpagide [45] , acetylharpagide [46] and L-tryptophan [47] were isolated from Scrophularia cryptophila (Scrophulariaceae). The compounds exhibited growth-inhibitory effect on bloodstream forms of T. b. rhodesiense with IC 50 values of 21.0, 26.9 and 4.1 μg/ml (59.7, 68.3 and 20 μM), respectively. For the reference drug, melarsoprol, an IC 50 value of 0.0098 μg/ml (0.025 μM) was obtained. None of the isolates was toxic on L6 cells (57) .
7-deacetylgedunin [48] and 7-oxo-7-deacetylgedunin [49] , both limonoid deguins, and kotschyin A [50] , a phragmalin-type limonoid orthoacetate, were isolated from Pseudocedrela kotschyi (Meliacae), a tree distributed from Senegal to Sudan. In the Sub-Saharan region P. kotschyi is commonly handled as a medical plant and in particular, in Nigeria it is used to treat sleeping sickness. The compounds possessed trypanocidal activity on bloodstream forms of T. b. rhodesiense with IC 50 values of 3.45, 3.40 and 11.60 μg/ml (7.8, 7.7 and 14.5 μM), respectively. In the applied concentrations 7-deacetylgedunin exhibited cytotoxicity to murine macrophage RAW cells with an SI value of 3.9. The IC 50 value for the reference drug, melarsoprol, was 0.004 μg/ml (0.010 μM) (61) .
Several polyacetylenes were isolated from Cussonia zimmermannii (Araliaceae), a tree growing in Kenya and Tanzania. 8-hydroxyheptadeca-4,6-diyn-3-yl acetate [51] , 8-hydroxyheptadeca-1-ene-4,6-diyn-3-yl acetate [52] and 16-acetoxy-11-hydroxyoctadeca-17-ene-12,14-diynyl acetae [53] respectively. Nevertheless, the potential of the most trypanocidal compound 3-amino-1-(2-aminoimidazoyl)-prop-1-ene is limited due to its high cytotoxicity. In this study, oroidin was identified as an uncompetitive inhibitor of Plasmodium falciparum FabI enzyme, which catalyzes the final step of the chain elongation in the fatty acid synthesis (63) .
Allium sativum (Liliaceae), called garlic, is used in traditional medicine against cardiovascular diseases, cancer, and infections. A major sulphur component of the garlic bulb is allicin (diallyl thiosulfinate), which exhibits antibacterial properties. A degradation product, ajoene [59] , is well known for its inhibitory effect on platelet aggregation and its cytotoxic, antifungal, antiviral, antitrypanosomal, and antimalarial activity. It was shown that ajoene inhibits the cholesterol synthesis and additionally its interference with the thiol homeostasis is suggested. Another degradation product is diallyl trisulfide, used in China for the treatment of bacterial, fungal and parasitic diseases. The IC 50 value of diallyl trisulfide [60] was 0.8-5.5 μg/ml (10-15 μM) when tested on several subspecies of T. brucei bloodstream forms, including T. b. rhodesiense. In concentrations ≤140 μM, no cytotoxicity was observed on fibroblasts (64) . The oily extract of the bulb of A. sativum administered i.p. 5.0 mg/ml per day suppressed trypanosomal infections in mice. The acetic acid/methanol fraction, which was suggested to be maintained by dially disulfide [61] , retained the trypanocidal effect of the crude extract and cured infected mice in i.p. application of 120 mg/ kg per day within four days. The authors anticipate that the trypanocidal effect was by interference with the parasites' synthesis of membrane lipids (65).
Conclusion
After prolonged exposure to drugs, parasites can frequently develop resistance towards chemotherapeutics. Natural products are a promising source for screening new drugs. Many compounds have been demonstrated to possess high trypanocidal activity and moderate cytotoxicity values towards mammalian cells in vitro, which might open avenues for further investigation. In addition, it has been shown that by derivatization of potent substances, related compounds with improved trypanocidal effects can be developed. This demonstrates the usefulness of natural products as novel lead structures as a basis for further drug development. Unfortunately, investigations in animal models as well as studies focusing on the mode of action of natural products towards trypanosomes are still rare.
The understanding of the molecular mode of action is of great importance to advance the development of potential new drugs. For example, use of microarray studies to show regulation of genes which are affected by drug treatment and to elucidate pathways in which the drug acts. When a target molecule is known, site-directed mutagenesis or QSAR (quantitative structure-activity relationship)-analysis are facilitating methods to reveal structure-activity-relationships, by investigation of the molecular properties which account for the biological action of a drug.
Although, a number of drug candidates have been investigated, research has still not continued to pass the initial in vitro investigations to a point of clinical studies. In our INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 22: 411-419, 2008 opinion, there is an urgent need for natural product research for the treatment of trypanosomal infections.
